Archer reaches key development milestone
Archer Materials Limited (ASX:AXE) has progressed its graphene-based biosensor technology development by building a first-phase prototype device to test the printing and performance of graphene inks produced from the inventory of Carbon Allotropes also known as graphene inks.
This development attracted the attention of investors with Archer’s share price up 7.7% to 14 cents, representing a 100% gain in the last six months, with the company trading not too far shy of its 12 month high.
Commenting on the company’s biosensor development, Archer chief executive Dr Mohammad Choucair said, “We have reached a key development milestone towards commercially exploiting the intellectual property (IP) underpinning the graphene-based biosensor technology.
‘’This achievement provides support for a full patent application that would give Archer exclusive rights to commercially benefit from the IP.
‘’The materials and processes used to build the prototypes are not prohibitively expensive, which is an advantage in the printable biosensor market.”
Materials sourced from wholly-owned subsidiary
Graphene acts as a sensing interface to detect biochemicals.
The high-quality graphene used in the graphene ink formulations is prepared from non-graphitic feedstocks and is available in the inventory of Carbon Allotropes, a wholly owned subsidiary of Archer.
Using in-house alternatives to graphite for processing graphene inks strengthens Archer’s independent IP ownership position.
The quantity and quality of the non-graphitic graphene used is suitable for rapid prototyping and future device integration.
Development of graphene-based biosensor technology
The development focus is on manufacturing a commercially viable graphene-based biosensor technology and the registration of a full patent application protecting the underlying materials technology intellectual property.
This involves optimising ink formulations and their processing methods linked to the provisional patent claims, and identifying transduction methods, bioreceptors, analytes, coupling and assay reagents for the proper function of the biosensor technology.
Archer intends to commercialise the biosensing technology by seeking to establish commercial partnerships, including licencing agreements, with highly resourced organisations including biotechnology companies that could allow for product scale, intellectual property transfer, and distribution channels.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.